Opinion|Videos|February 24, 2025
Key Takeaways for Patient-Centered Management of Atopic Dermatitis
Author(s)Raj Chovatiya, MD, PhD, MSCI
The panelist discusses how systemic atopic dermatitis therapies now emphasize targeted biologics and Janus kinase inhibitors, requiring personalized approaches, comprehensive monitoring, and holistic patient management.
Advertisement
Episodes in this series
Video content above is provided by the following:
- Based on our discussion, what key insights or new perspectives could you share regarding treatment considerations for systemic therapies for atopic dermatitis?
- What take-home messages or practice pearls do you have for clinicians treating patients with atopic dermatitis?
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
2
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
5